Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir added to stable HAART in HIV-1 with low CD4 recovery
NCT00562510Phase 3Terminated
- Start
- Aug 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Raltegravir with Placebo (2 arms). Primary endpoint: Proportion of subjects increasing CD4 count > 50 cells/mm³ at 48 weeks. Started Aug 2008; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00562510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562510.